title: Photodynamic therapy for Barrett's esophagus with dysplasia and/or early stage carcinoma: long-term results.
abstract: BACKGROUND
  Photodynamic therapy has been shown to eliminate Barrett's dysplasia. This report presents long-term follow-up data after photodynamic therapy of Barrett's esophagus with high-grade dysplasia, low-grade dysplasia, or early stage carcinoma.
  
  
  METHODS
  Porfimer-photodynamic therapy was performed in 103 patients. The Nd:YAG laser was used to photoablate small areas of residual or untreated Barrett's mucosa. Acid suppression was maintained in all patients (omeprazole, 20 mg twice a day).
  
  
  RESULTS
  Mean follow-up was 50.65 (SD 20.57) months (range 2-122 months). For the 82 patients not lost to follow-up, mean follow-up was 58.5 (12.89) months (range 41-132 months). After photodynamic therapy, the length of Barrett's mucosa decreased by a mean of 6.92 cm (range 1-22 cm). Of the 65 patients with high-grade dysplasia, 60 (94%) had elimination of high-grade dysplasia. Three (4.6%) patients developed subsquamous adenocarcinoma. Subsquamous, nondysplastic, metaplastic epithelium was found in 4 patients (4.9%). Strictures occurred in 18% with one session of photodynamic therapy, and 50% with two treatments, 30% overall. For the 103 patients, intention-to-treat success rates were 92.9%, 77.5%, and 44.4% for, respectively, low-grade dysplasia, high-grade dysplasia, and early stage carcinoma groups.
  
  
  CONCLUSIONS
  Porfimer-photodynamic therapy with supplemental Nd:YAG photoablation and continuous treatment with omeprazole reduces the length of Barrett's mucosa, eliminates high-grade dysplasia, and, by comparison with historical data, may reduce the expected frequency of carcinoma.
authors.affiliation: Laser Center, Thompson Cancer Survival Center, Knoxville, Tennessee, USA.
authors.forename: Bergein F
authors.initials: BF
authors.lastname: Overholt
authors.forename: Masoud
authors.initials: M
authors.lastname: Panjehpour
authors.forename: Daniel L
authors.initials: DL
authors.lastname: Halberg
mesh_terms: D000230:Adenocarcinoma / Q000473:pathology; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000897:Anti-Ulcer Agents / Q000627:therapeutic use; D001471:Barrett Esophagus / Q000188:drug therapy* / Q000473:pathology; D004938:Esophageal Neoplasms / Q000150:complications*; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008679:Metaplasia / Q000473:pathology; D008875:Middle Aged; D009853:Omeprazole / Q000627:therapeutic use; D010778:Photochemotherapy / Q000379:methods; D011230:Precancerous Conditions / Q000150:complications*
chemical_list: D000897:Anti-Ulcer Agents; D009853:Omeprazole